Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2259-2265

  Aghajanian, Carol ^{a,b,c,d,e,f,g,h,i}   Sill, Michael W ^{a,b,c,d,e,f,g,h,i}   Darcy, Kathleen M ^{a,b,c,d,e,f,g,h,i}   Greer, Benjamin ^{a,b,c,d,e,f,g,h,i}   McMeekin, D Scott ^{a,b,c,d,e,f,g,h,i}   Rose, Peter G ^{a,b,c,d,e,f,g,h,i}   Rotmensch, Jacob ^{a,b,c,d,e,f,g,h,i}   Barnes, Mack N ^{a,b,c,d,e,f,g,h,i}   Hanjani, Parviz ^{a,b,c,d,e,f,g,h,i}   Leslie, Kimberly K ^{a,b,c,d,e,f,g,h,i}  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^h ABINGTON MEMORIAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN A;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG ACTIVITY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EDEMA; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; FEMALE; GYNECOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHINITIS; SKIN DISEASE; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957949444     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.6397     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, et al: Cancer Statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 22:2159-2166, 2004 (Pubitemid 41095150)
3. Fiorica M, Brunetto VL, Hanjani P, et al: Phase II trial of alternating course of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 92:10-14, 2004 (Pubitemid 38147365)
4. Whitney CW, Brunetto VL, Zaino RJ, et al: Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 92:4-9, 2004 (Pubitemid 38147364)
5. Lentz SS, Brady MF, Major FJ, et al: Highdose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 14:357-361, 1996 (Pubitemid 26050995)
6. Thigpen JT, Brady MF, Alvarez RD, et al: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736-1744, 1999 (Pubitemid 29269242)
7. Thigpen T, Brady MF, Homesley HD, et al: Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 19:364-367, 2001 (Pubitemid 32112847)
8. Oza AM, Elit L, Biagi J, et al: Molecular correlates associated with a phase II study of temsirolimus (CCI-77) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. J Clin Oncol 24:121s, 2006 (suppl; abstr 3003)
9. Oza AM, Elit L, Provencher J, et al: NCIC CTG IND 160b: Phase II study of CCI-779 (temsirolimus) in patients with metastatic and/or locally advanced recurrent endometrial cancer. J Clin Oncol 26:296s, 2008 (suppl; abstr 5516)
10. Slomovitz BM, Lu KH, Johnston T, et al: A phase II study of the oral mammalian target of rapamycin, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116:5415-5419, 2010
11. Colombo N, McMeekin S, Schwartz P, et al: A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 25:278s, 2007 (suppl; abstr 5516)
12. Fleming GF, Sill MW, Darcy KM, et al: Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 116:15-20, 2010
13. Oza AM, Eisenhauer EA, Elit L, et al: Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 26:4319-4325, 2008
14. Leslie KK, Sill MW, Darcy KM, et al: Efficacy and safety of gefitinib (Iressa, ZD1839) and potential prognostic value of soluble EGFR, EGFR mutations and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. J Clin Oncol 27, 2009 (suppl; abstr e16542)
15. Slomovitz B, Schmeler K, Miller D, et al: Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Gynecol Oncol 116:13, 2010 (suppl 1; abstr)
16. Correa R, Mackay H, Hirte HW, et al: A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. J Clin Oncol 28:399s, 2010 (suppl; abstr 5038)
17. Nimeiri HS, Oza AM, Morgan RJ, et al: Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol 26:313s, 2008 (suppl; abstr 5585)
18. McMeekin DS, Sill MW, Benbrook D, et al: A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. Gynecol Oncol 105:508-516, 2007 (Pubitemid 46591977)
19. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
20. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
21. Monk BJ, Sill MW, Burger RA, et al: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 27:1069-1074, 2009
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
23. Rose PG, Blessing JA, Lewandowski GA, et al: A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 63:101-104, 1996 (Pubitemid 26337974)
24. Lincoln S, Blessing JA, Lee RB, et al: Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 88:277-281, 2003 (Pubitemid 36335809)
25. Moore DH, Blessing JA, Dunton C, et al: Evaluation of dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 75:473-475, 1999
26. Muggia FM, Blessing JA, Sorosky J, et al: Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 20:2360-2364, 2002 (Pubitemid 34441664)
27. Plaxe S, Blessing JA, Husseindazeh N, et al: Evaluation of pyrazoloacridine (PZA) (NSC #366140) in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 84:241-244, 2002 (Pubitemid 34136774)
28. Miller DS, Blessing JA, Lentz SS, et al: Evaluation of topotecan in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 87:247-251, 2002 (Pubitemid 36034643)
29. Fracasso PM, Blessing JA, Molpus KL, et al: Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 103:523-526, 2006 (Pubitemid 44740100)
30. Schilder R, Blessing JA, Pearl ML, et al: Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Invest New Drugs 22:343-349, 2004 (Pubitemid 39012575)
31. Grendys E, Blessing J, Burger R, et al: A phase II evaluation of flavorpiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 98:249-253, 2005 (Pubitemid 41019113)
32. Sill MW, Yothers G: A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials: Technical Report 06-08, Department of Biostatistics, UniversityatBuffalo.http:// sphhp.buffalo.edu/biostat/research/techreports/UB-Biostatistics-TR0608.pdf
33. Hecht JL, Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24:4783-4791, 2006 (Pubitemid 46630943)
34. Mutter GL, Lin MC, Fitzgerald JT, et al: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92:924-930, 2000
35. Kurose K, Zhou XP, Araki T, et al: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158:2097-2106, 2001 (Pubitemid 32545195)
36. Zhu X, Kwon CH, Schlosshauer PW, et al: PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 61:4569-4575, 2001 (Pubitemid 32685791)
37. Oda K, Stokoe D, Takentani Y, et al: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669-10673, 2005 (Pubitemid 41713332)